Sanofi (SNY) Return on Assets ROA from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, Average High and Low, Fundamental Ratios from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Sanofi  (NASDAQ: SNY)


Sanofi's ROA from the fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Sanofi's ROA in the fourth quarter of 2025?
Sanofi achieved a return on average assets (ROA) of 6.19 % in its fourth quarter of 2025, this is above SNY's average return on assets of 5.52%.
Sanofis assets during the 12 months ending in the fourth quarter of 2025 are valued at $142 billion

ROA has improved compared to 4.38% in the third quarter of 2025, due to net income growth.

However, within the Healthcare sector 158 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from to 1164.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Total Assets Change -4.46 % -4.51 % -4.84 % -4.51 % 7.97 %
Y / Y Net Income Change 39.75 % - - - 3.35 %
Net Income (TTM) in million 8,793 6,292 6,292 6,292 6,292
Return On Assets (TTM) 6.19 % 4.38 % 4.33 % 4.28 % 4.23 %
SNY's Total Ranking # 1164 # # # # 1574
Total Assets (TTM) in million 142,106 142,022 142,022 142,022 148,734
Seq. Total Assets Change 0.06 % 0 % 0 % -4.51 % 0 %
Seq. Net Income Change - - - - -

SNY's 5 Years Annual ROA >> Back to SNY Management Effectiveness >> Compare SNY ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 60
Sector # 159
Overall # 1157

Return On Assets Statistics
High Average Low
10.78 %
5.52 %
2.52 %
(Dec 31 2020)  





Financial Statements
Sanofi's Assets $ 142,106 million SNY's Balance sheet
Sanofi's Income $ 8,793 million Quarterly SNY's Income Statement
SNY's Income by Division See SNY's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change -4.51 % 7.97 % -0.09 % -18.98 % 29.48 %
Total Assets in million 142,022 148,734 137,753 137,878 170,180
Y / Y Net Income Change 39.75 % 3.35 % -35.93 % 27.92 % -46.3 %
Net Income in million 8,793 6,292 6,088 9,502 7,428
Annual Return On Assets 6.19 % 4.23 % 4.42 % 6.89 % 4.36 %

SNY's 5 Years Annual ROA >> Back to SNY Management Effectiveness >> Compare SNY ROA to its Competitors



Comment on SNY's ROA in the fiscal year ending 2025
In the fiscal year 2025 ROA improved to 6.19 % compared to prior year, due to annual net income growth of 39.75 % to $8,793.12 million, and due to decline of value in Sanofi's assets by -4.51 % to $142,021.60 million, compared to $142,021.60 a year before.


More Return On Assets Ratios
SNY's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
SNY's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for SNY's Competitors
Subscribers only: Roa for Sanofi's Suppliers
Subscribers only: Return On Assets for SNY's Customers

You may also want to know
SNY's Roi SNY's Inventory Turnover Ratio SNY's Growth Rates SNY's Dividend Comparisons
SNY's Profitability Ratios SNY's Asset Turnover Ratio SNY's Dividend Growth
SNY's Roe SNY's Valuation Ratios SNY's Financial Strength Ratios SNY's Dividend Payout Ratio



Companies with similar Return On Assets at Dec 31 2025, within Healthcare Sector ROA
Electromed Inc   16.83 %
Arrowhead Pharmaceuticals Inc   16.32 %
Vertex Pharmaceuticals Inc  16.23 %
Chemed Corporation  16.06 %
Mimedx Group Inc   15.89 %
Sbc Medical Group Holdings Incorporated  15.69 %
Indivior Pharmaceuticals Inc   15.43 %
Puma Biotechnology Inc   15.36 %
Argenx Se  14.88 %
Gilead Sciences Inc   14.82 %
Merck and Co Inc   14.64 %
Intuitive Surgical Inc   14.53 %
Strata Critical Medical Inc   14.15 %
Halozyme Therapeutics Inc   14.09 %
Black Diamond Therapeutics Inc   13.91 %
Johnson and Johnson  13.76 %
Harmony Biosciences Holdings inc   13.67 %
Illumina Inc   13.55 %
Waters Corporation  13.35 %
Keros Therapeutics Inc   13.27 %
Prestige Consumer Healthcare Inc   13.25 %
Spero Therapeutics Inc   13.04 %
Hca Healthcare Inc   12.98 %
Novartis Ag  12.59 %
Embecta Corp   12.51 %
Sab Biotherapeutics Inc   12.51 %
Carlisle Companies Incorporated  12.51 %
Aveanna Healthcare Holdings Inc   12.41 %
West Pharmaceutical Services Inc   12.38 %
Inmode Ltd   12.24 %

Date modified: 2026-06-24T10:07:58+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.